MADISON, WIS. (PRWEB) AUGUST 15, 2018
EyeKor, Inc., a leading Software-as-a-Service (SaaS) company providing comprehensive image management and analysis for ophthalmic clinical and preclinical studies, today announced its ranking on the 2018 Inc. magazine 5000 list of the nation’s fastest-growing private companies. With 1045% three-year revenue growth, EyeKor is positioned at #484, entering the prestigious circle of the top 500. To date, EyeKor has created 26 job opportunities in the State of Wisconsin.
EyeKor was founded in 2012 and developed EXCELSIOR™, its comprehensive and innovative cloud-based software platform which provides state-of-the-art solutions for the management, analysis, and interpretation of ophthalmic images in clinical trials. With extensive software functionalities for image viewing, analysis, and workflow management, EXCELSIOR™ ultimately address and solve many of the problems sponsors face throughout the drug development process by harmonizing data from different manufacturers, removing the dependency on manufacturer proprietary software, increasing the efficiency and transparency of data handling, and providing rapid turnaround time for image analysis.
A second version of EXCELSIOR™ has been designed and engineered specifically for the management of data in preclinical studies, enhancing comparison and translatability of data between preclinical and clinical studies, and ultimately improving and streamlining the drug development process from discovery to approval.
“Our mission at EyeKor is straightforward – to provide companies engaged in ophthalmic drug development with services and expertise that enable them to achieve their goals with optimal efficiency, while also providing an innovative technology that will help lead the industry into a new era of therapeutic development and vision care”, said EyeKor’s CEO, Dr. Christopher J. Murphy. “The services we provide at EyeKor, the cutting-edge functionalities provided by our EXCELSIOR™ platform, and the commitment of our team members to excellence, collectively enable us to be a trusted partner in the drug development industry, a role that is at the core of everything we do.”
“The EXCELSIOR™ SaaS platform is the heart of our innovation and disruptive contribution to the field of ophthalmic drug development,” added Dr. Yijun Huang, EyeKor’s President and CTO. “Leveraging the benefit of cloud-based infrastructure, EXCELSIOR™ makes collaboration of stakeholders at geographically dispersed locations easier and more impactful. EXCELSIOR™ is built as a medical device with FDA 510(k) clearance and is HIPAA and 21 CFR part 11 compliant.”
“The EXCELSIOR™ platform is applauded by our pharmaceutical and biotech clients in part because it can enable virtually real-time access to images and workflow progress to research teams and central reading center staff,” said Dr. Ronald Danis, EyeKor’s CSO and Co-Founder. “In the short time from the inception of the company, we have engaged in nearly 70 clinical trials and collected data from more than 1000 clinical sites from 42 countries. There are more than 10 million images hosted in EXCELSIOR™ to date.”